Visual Dysfunction in Diabetes
The Science of Patient Impairment and Health Care
(Sprache: Englisch)
An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
160.49 €
80 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Visual Dysfunction in Diabetes “
An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living daily with diabetes rather than considering diabetic retinopathy solely as a medical problem, and to explore what we know and don't know about the ways diabetes affect the eye. With the plethora of new information being generated, there are still a series of fundamental questions that must be addressed if effective treatments for diabetic retinopathy are to be found and applied. Developed by a renowned group of authorities, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers responses and context for a range of questions, such as: do metabolic factors beyond glucose contribute to vision-threatening diabetic retinopathy? If so, how do these lead to vision impairment? Is diabetic retinopathy a response to systemic metabolic abnormalities or are there unique ocular problems related to insulin resistance? What is the relationship between the neural, vascular, and inflammatory abnormalities in diabetic retinopathy? Do they represent a pathological cascade induced sequentially or simultaneous responses to one or more metabolic perturbations? The authors note that if we do not address these types of questions, it is possible that the long process of developing new therapeutics will target only one arm of the pathology and leave the retina open to damaging consequences of the others. State-of-the-art, comprehensive, and an invaluable addition the research and clinical literature, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers guidance and a significant step toward new scientific approaches that can lessen the devastating vision impairment associated with diabetes.
Klappentext zu „Visual Dysfunction in Diabetes “
An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living daily with diabetes rather than considering diabetic retinopathy solely as a medical problem, and to explore what we know and don't know about the ways diabetes affect the eye. With the plethora of new information being generated, there are still a series of fundamental questions that must be addressed if effective treatments for diabetic retinopathy are to be found and applied. Developed by a renowned group of authorities, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers responses and context for a range of questions, such as: do metabolic factors beyond glucose contribute to vision-threatening diabetic retinopathy? If so, how do these lead to vision impairment? Is diabetic retinopathy a response to systemic metabolic abnormalities or are there unique ocular problems related to insulin resistance? What is the relationship between the neural, vascular, and inflammatory abnormalities in diabetic retinopathy? Do they represent a pathological cascade induced sequentially or simultaneous responses to one or more metabolic perturbations? The authors note that if we do not address these types of questions, it is possible that the long process of developing new therapeutics will target only one arm of the pathology and leave the retina open to damaging consequences of the others. State-of-the-art, comprehensive, and an invaluable addition the research and clinical literature, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers guidance and a significant step toward new scientific approaches that can lessen the devastating vision impairment associated with diabetes.Inhaltsverzeichnis zu „Visual Dysfunction in Diabetes “
Introduction Diabetic Retinopathy - what we know, don't know, and need to know - Tom Gardner Living with Diabetic RetinopathyCh.1 A Patient's viewpoint: Heather Stuckey
Ch.2 What patients with diabetes see-and don't see: subjective and objective visual function changes - Shelly Boyd
Ch.3 How do I know I have diabetic retinopathy - a clinician's view? - David Quillen Prevalence, Public Awareness, and Screening Methods
Ch.4 Epidemiology & Economics - John Javitt
Ch.5 Correlation between the presence and severity of diabetic retinopathy in families with diabetes - Victor Gonzalez
Ch.6 Increasing public awareness of the diabetes endemic - Ian Constable
Ch.7 Nutrition and diabetes- David Nathan
Ch.8 Diabetic retinopathy screening - progress and complications - Peter Scanlon Diagnosing Diabetic Retinopathy
Ch.9 Measurements of retinal blood flow, vascular leakage, and oxygenation - Einer Stefansson
Ch.10 Optical imaging - Confocal microscopy to detect retinal vasculature - Martin Friedlander
Ch.11 Structural imaging - OCT - M. Larsen
Ch.12 Functional imaging - ERG - Anthony Adams How Diabetes Affects the Eye
Ch.13 Clinical phenotypes (reclassification) - J. Cunha-Vaz
Ch.14 Vascular changes - David Antonetti & Tom Gardiner (Belfast)
Ch.15 Neuronal changes - Alistair Barber/Greg Jackson
Ch.16 Inflammatory changes - Mark Tso
Ch.17 Other Ocular Complications of Diabetes - Shoja MR New Approaches to Diabetic Retinopathy
Ch.18 New insights in the pathogenesis of diabetic retinopathy using a proteomic approach - Retina - Quin GG
Ch.19 Vitreous proteomics - Ed Feener
Ch.20 Genomics - Bill Freeman
Ch.21 Genome-wide linkage analyses to identify Loci for diabetic retinopathy - Kang Zhang (Utah) Risk Factors
Ch.22 Diabetic retinopathy correlates with increased incidence of cardiovascular events -Cheung N
Ch.23 Pregnancy and rate of progression of diabetic retinopathy - Sheth BP Molecular Mechanisms
... mehr
that Could Trigger Visual Dysfunction in Diabetes Introduction - Tom Gardner
Ch.24 Inflammation in the early pathogenesis of diabetic retinopathy -beauty and beast. - Chris Norbury (Hershey)
Ch.25 Oxidative stress and diabetic retinopathy. - Catherine Whiteside
Ch.26 Glucose induced cellular signaling in diabetic retinopathy - Chakrabarti S
Ch.27 The AGE/RAGE axis in early diabetic retinopathy - Schmidt AM
Ch.28 Proteases and the retinal vasculature (and maybe the whole retina!) - Arup Das.
Ch. 29 IGFBP3 and retinal vessel growth. Smith LE
Ch.30 PEDF, VEGF, CTGF review - JX Ma
Ch.31 A decrease in the expression of somatostatin is an early event in diabetic retinopathy - Carrasco E
Ch.32 Connective tissue and connective tissue growth factor in diabetic retinopathy - Schlingemann RO
Ch.33 Molecular regulation of endothelial cell tight junctions and the blood retinal barrier - Antonetti DA
Ch.34 Pericytes and diabetic retinopathy - Puro DG
Ch.35 Leukostasis - Adamis, AP
Ch.36 Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. - Khalfaoui T,
Ch.37 Azurocidin as a Permeability Factor in the Retina - Hafezi-Moghadam A
Ch.38 Retinal arteriolar hemodynamic response to a combined isocapnic hyperoxia and glucose provocation in early sight-threatening diabetic retinopathy. - Devenyi RG.
Ch. 39 Urinary 8-hydroxydeoxyguanosine (8-OHdG) levels in diabetic retinopathy patients. - Steve Abcouwer
Ch.40 Tyrosine nitration in the molecular mechanisms of diabetic retinopathy. - Crabb JW Limiting Vision Loss - Experimental Therapies Introduction - Tom Gardner Vascular Control
Ch.41 Ranibizumab for macular edema in diabetes - Quan Dong Nguyen
Ch.42 Bevacizumab for PDR - Qin H
Ch.43 Capillary degeneration in the early stages of diabetic retinopathy. Kern TS
Ch.44 Renin-angiotensin system in the eye - Jennifer Wilkinson-Berka
Ch.45 Statins and the BRB -Ruth Caldwell Neuronal Control
Ch.46 Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. Lahdenranta J
Ch.47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes - Zhang J and Xu GT Inflammatory Control
Ch.48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Sawada N
Ch.49 Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy - Clarke M, Dodson PM.
Ch. 50 Intravitreal triamcinolone acetonide for diabetic retinopathy - Jonas JB
Ch.51 Aptamers that bind PDGF-B are a potential treatment for proliferative retinopathies. Akiyama H
Ch.52 Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy - Lin J Regenerative Approaches
Ch.53 Islet Cell/stem cell transplantation - Warnock GL (Canada) Future Directions
Ch.54 How do we improve the translational research process? What do we need to know? Barbara Araneo
Conclusion - Tom Gardner/>
Ch.47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes - Zhang J and Xu GT Inflammatory Control
Ch.48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Sawada N
Ch.49 Ruboxistaurin show
Ch.24 Inflammation in the early pathogenesis of diabetic retinopathy -beauty and beast. - Chris Norbury (Hershey)
Ch.25 Oxidative stress and diabetic retinopathy. - Catherine Whiteside
Ch.26 Glucose induced cellular signaling in diabetic retinopathy - Chakrabarti S
Ch.27 The AGE/RAGE axis in early diabetic retinopathy - Schmidt AM
Ch.28 Proteases and the retinal vasculature (and maybe the whole retina!) - Arup Das.
Ch. 29 IGFBP3 and retinal vessel growth. Smith LE
Ch.30 PEDF, VEGF, CTGF review - JX Ma
Ch.31 A decrease in the expression of somatostatin is an early event in diabetic retinopathy - Carrasco E
Ch.32 Connective tissue and connective tissue growth factor in diabetic retinopathy - Schlingemann RO
Ch.33 Molecular regulation of endothelial cell tight junctions and the blood retinal barrier - Antonetti DA
Ch.34 Pericytes and diabetic retinopathy - Puro DG
Ch.35 Leukostasis - Adamis, AP
Ch.36 Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. - Khalfaoui T,
Ch.37 Azurocidin as a Permeability Factor in the Retina - Hafezi-Moghadam A
Ch.38 Retinal arteriolar hemodynamic response to a combined isocapnic hyperoxia and glucose provocation in early sight-threatening diabetic retinopathy. - Devenyi RG.
Ch. 39 Urinary 8-hydroxydeoxyguanosine (8-OHdG) levels in diabetic retinopathy patients. - Steve Abcouwer
Ch.40 Tyrosine nitration in the molecular mechanisms of diabetic retinopathy. - Crabb JW Limiting Vision Loss - Experimental Therapies Introduction - Tom Gardner Vascular Control
Ch.41 Ranibizumab for macular edema in diabetes - Quan Dong Nguyen
Ch.42 Bevacizumab for PDR - Qin H
Ch.43 Capillary degeneration in the early stages of diabetic retinopathy. Kern TS
Ch.44 Renin-angiotensin system in the eye - Jennifer Wilkinson-Berka
Ch.45 Statins and the BRB -Ruth Caldwell Neuronal Control
Ch.46 Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. Lahdenranta J
Ch.47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes - Zhang J and Xu GT Inflammatory Control
Ch.48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Sawada N
Ch.49 Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy - Clarke M, Dodson PM.
Ch. 50 Intravitreal triamcinolone acetonide for diabetic retinopathy - Jonas JB
Ch.51 Aptamers that bind PDGF-B are a potential treatment for proliferative retinopathies. Akiyama H
Ch.52 Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy - Lin J Regenerative Approaches
Ch.53 Islet Cell/stem cell transplantation - Warnock GL (Canada) Future Directions
Ch.54 How do we improve the translational research process? What do we need to know? Barbara Araneo
Conclusion - Tom Gardner/>
Ch.47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes - Zhang J and Xu GT Inflammatory Control
Ch.48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Sawada N
Ch.49 Ruboxistaurin show
... weniger
Bibliographische Angaben
- 2011, XV, 379 Seiten, Maße: 18,3 x 26 cm, Gebunden, Englisch
- Herausgegeben: Joyce Tombran-Tink, Colin J. Barnstable, Thomas W. Gardner
- Verlag: Springer, Berlin
- ISBN-10: 160761149X
- ISBN-13: 9781607611493
- Erscheinungsdatum: 15.12.2011
Sprache:
Englisch
Pressezitat
"It succeeds in summarizing recent advancements in our knowledge in the field with a well illustrated presentation, up-to-date references, and an authorship selected from an international group of respected investigators with proven contributions to the field. ... It could be recommended as a reference for anyone interested in the basic mechanisms of the disease, its ocular manifestations, and treatment options." (Radouil Tzekov, Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 253 (6), June, 2015)
Kommentar zu "Visual Dysfunction in Diabetes"
0 Gebrauchte Artikel zu „Visual Dysfunction in Diabetes“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Visual Dysfunction in Diabetes".
Kommentar verfassen